Corrected: Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial
08/09/2026 14:14
CORRECTED-Amgen-AstraZeneca cancer drug combo hits main survival goal in late-stage trial Corrects headline to say Amgen-AstraZeneca drug combo, not AstraZeneca's drug combo
Sept 8 (Reuters) - AstraZeneca AZN.L said on Tuesday its cancer drug Imfinzi combined with Amgen's AMGN.O targeted immunotherapy Imdelltra significantly improved overall survival in first-line extensive-stage small cell lung cancer in a late-stage trial.
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Leroy Leo)
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines